Nasdaq · Healthcare
Zymeworks Inc. (ZYME)
As-reported financials and recent SEC filings for Zymeworks Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$106.0M
Net income
$-81.1M
Net margin
-76.6%
Diluted EPS
$-1.08
ROE
-30.2%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $106.0M | $76.3M | $76.0M | $412.5M | $26.7M |
| Gross profit | — | — | — | — | — |
| Operating income | $-92.5M | $-137.1M | $-138.1M | $130.5M | $-215.6M |
| Net income | $-81.1M | $-122.7M | $-118.7M | $124.3M | $-211.8M |
| Diluted EPS | $-1.08 | $-1.62 | $-1.72 | $1.90 | $-4.61 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-06
View on EDGAR →8-K2026-06-29
View on EDGAR →42026-05-15
View on EDGAR →32026-05-15
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →8-K2026-05-14
View on EDGAR →10-Q2026-05-07
View on EDGAR →8-K2026-05-07
View on EDGAR →Largest Healthcare peers
Go deeper on ZYME
Search Zymeworks Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.